Buprenorphine Buccal Film for Chronic Pain Management

References

• Dahlhamer J , LucasJ , ZelayaCet.al Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb. Mortal. Wkly Rep.67(36), 1001–1006 (2018).
   PubMed Web of Science ®Google Scholar
• Davis MP , PasternakG , BehmB. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs78(12), 1211–1228 (2018).
   PubMed Web of Science ®Google Scholar
• Reuben DB , AlvanzoAA , AshikagaTet.al National Institutes of Health pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Ann. Intern. Med.162(4), 295–300 (2015).
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse . Prescription opioids (2019). https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
   Google Scholar
• Hedegaard H , MiniñoAM , WarnerM. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief No. 329, November 2018. https://www.cdc.gov/nchs/products/databriefs/db329.htm
   Google Scholar
• Tzschentke TM . Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl)161(1), 1–16 (2002).
   PubMed Web of Science ®Google Scholar
• Gudin J , FudinJ. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. doi:10.1007/s40122-019-00143-6 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Khanna IK , PillarisettiS. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. J. Pain Res.8, 859–870 (2015).
   PubMed Web of Science ®Google Scholar
• Ahmadi J , JahromiMS , EhsaeiZ. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials19(1), 462 (2018).
   PubMedGoogle Scholar
• Likar R . Transdermal buprenorphine in the management of persistent pain - safety aspects. Ther. Clin. Risk Manag.2(1), 115–125 (2006).
   PubMedGoogle Scholar
• Rothman RB , GorelickDA , HeishmanSJet.al An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J. Subst. Abuse Treat.18(3), 277–281 (2000).
   PubMed Web of Science ®Google Scholar
• Stein C , MachelskaH. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol. Rev.63(4), 860–881 (2011).
   PubMed Web of Science ®Google Scholar
• Hallinan R , ByrneA , AghoK , McmahonCG , TynanP , AttiaJ. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int. J. Androl.32(2), 131–139 (2009).
   PubMed Web of Science ®Google Scholar
• Davis MP . Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J. Support. Oncol.10(6), 209–219 (2012).
   PubMedGoogle Scholar
• Böhme K . Buprenorphine in a transdermal therapeutic system – a new option. Clin. Rheumatol.21(Suppl. 1), S13–S16 (2002).
   PubMed Web of Science ®Google Scholar
• Breivik H , LjosaaTM , Stengaard-PedersenKet.al A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand. J. Pain1(3), 122–141 (2010).
   PubMedGoogle Scholar
• Gianni W , MadaioAR , CeciMet.al Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J. Pain Symptom Manage.41(4), 707–714 (2011).
   PubMed Web of Science ®Google Scholar
• Gordon A , CallaghanD , SpinkDet.al Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin. Ther.32(5), 844–860 (2010).
   PubMed Web of Science ®Google Scholar
• Gordon A , RashiqS , MoulinDEet.al Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res. Manage.15(3), 169–178 (2010).
   PubMed Web of Science ®Google Scholar
• Hakl M . Transdermal buprenorphine in clinical practice: a multicenter, postmarketing study in the Czech Republic, with a focus on neuropathic pain components. Pain Manage.2(2), 169–175 (2012).
   PubMedGoogle Scholar
• Karlsson J , SöderströmA , AugustiniBG , BerggrenAC. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. Curr. Med. Res. Opin.30(4), 575–587 (2014).
   PubMed Web of Science ®Google Scholar
• Karlsson M , BerggrenAC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin. Ther.31(3), 503–513 (2009).
   PubMed Web of Science ®Google Scholar
• Leng X , LiZ , LvHet.al Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin. J. Pain31(7), 612–620 (2015).
   PubMed Web of Science ®Google Scholar
• Likar R , KayserH , SittlR. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin. Ther.28(6), 943–952 (2006).
   PubMed Web of Science ®Google Scholar
• Likar R , LorenzV , Korak-LeiterM , KagerI , SittlR. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Clin. Ther.29(8), 1591–1606 (2007).
   PubMed Web of Science ®Google Scholar
• Likar R , VadlauEM , BreschanC , KagerI , Korak-LeiterM , ZiervogelG. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin. J. Pain24(6), 536–543 (2008).
   PubMed Web of Science ®Google Scholar
• Miller K , YarlasA , WenWet.al Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin. Pharmacother.14(3), 269–277 (2013).
   PubMed Web of Science ®Google Scholar
• Miller K , YarlasA , WenWet.al The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health. Clin. J. Pain30(12), 1015–1022 (2014).
   PubMed Web of Science ®Google Scholar
• Pace MC , PassavantiMB , GrellaEet.al Buprenorphine in long-term control of chronic pain in cancer patients. Front. Biosci.12, 1291–1299 (2007).
   PubMed Web of Science ®Google Scholar
• Pota V , BarbarisiM , SansonePet.al Combination therapy with transdermal buprenorphine and pregabalin for chronic low back pain. Pain Manage.2(1), 23–31 (2012).
   PubMedGoogle Scholar
• Ripa SR , MccarbergBH , MuneraC , WenW , LandauCJ. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. Expert Opin. Pharmacother.13(9), 1229–1241 (2012).
   PubMed Web of Science ®Google Scholar
• Serpell M , TripathiS , ScherzingerS , Rojas-FarrerasS , OkscheA , WilsonM. Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK observational study. Patient9(1), 35–46 (2016).
   PubMedGoogle Scholar
• Silverman S , RaffaRB , CataldoMJ , KwarcinskiM , RipaSR. Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system. J. Pain Res.10, 1255–1263 (2017).
   PubMed Web of Science ®Google Scholar
• Sittl R , GriessingerN , LikarR. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.25(1), 150–168 (2003).
   PubMed Web of Science ®Google Scholar
• Skvarc NK . Transdermal buprenorphine in clinical practice: results from a multicenter, noninterventional postmarketing study in Slovenia. Pain Manage.2(2), 177–183 (2012).
   PubMedGoogle Scholar
• Sorge J , SittlR. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther.26(11), 1808–1820 (2004).
   PubMed Web of Science ®Google Scholar
• Steiner D , MuneraC , HaleM , RipaS , LandauC. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J. Pain12(11), 1163–1173 (2011).
   PubMed Web of Science ®Google Scholar
• Steiner DJ , SitarS , WenWet.al Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J. Pain Symptom Manage.42(6), 903–917 (2011).
   PubMed Web of Science ®Google Scholar
• Vondráčková D . Transdermal buprenorphine in clinical practice: a multicenter, noninterventional postmarketing study in the Czech Republic. Pain Manage.2(2), 163–168 (2012).
   PubMedGoogle Scholar
• Yarlas A , MillerK , WenWet.al A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. J. Pain14(1), 14–23 (2013).
   PubMed Web of Science ®Google Scholar
• Yarlas A , MillerK , WenWet.al Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. Postgrad. Med.127(1), 38–45 (2015).
   PubMed Web of Science ®Google Scholar
• James IG , O’brienCM , McdonaldCJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J. Pain Symptom Manage.40(2), 266–278 (2010).
   PubMed Web of Science ®Google Scholar
• Yarlas A , MillerK , WenWet.al Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low back pain: results from two randomized controlled trials. Pain Pract.16(3), 345–358 (2016).
   PubMed Web of Science ®Google Scholar
• Gimbel J , SpieringsEL , KatzN , XiangQ , TzanisE , FinnA. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a Phase 3, enriched enrollment, randomized withdrawal study. Pain157(11), 2517–2526 (2016).
   PubMed Web of Science ®Google Scholar
• Hale M , UrdanetaV , KirbyMT , XiangQ , RauckR. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J. Pain Res.10, 233–240 (2017).
   PubMed Web of Science ®Google Scholar
• Rauck RL , PottsJ , XiangQ , TzanisE , FinnA. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad. Med.128(1), 1–11 (2016).
   PubMed Web of Science ®Google Scholar
• Bullingham RE , McquayHJ , DwyerD , AllenMC , MooreRA. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br. J. Clin. Pharmacol.12(2), 117–122 (1981).
   PubMed Web of Science ®Google Scholar
• Moody DE , FangWB , MorrisonJ , Mccance-KatzE. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend.118(2-3), 479–483 (2011).
   PubMed Web of Science ®Google Scholar
• Corli O , FlorianiI , RobertoAet.al Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized Phase IV ‘real life’ trial on the variability of response to opioids. Ann. Oncol.27(6), 1107–1115 (2016).
   PubMed Web of Science ®Google Scholar
• Belbuca [package insert] . BioDelivery Sciences International, Inc.Raleigh, NC, USA (2019).
   Google Scholar
• Butrans [package insert] . Purdue Pharma L.P. Stamford, CT, USA (2019).
   Google Scholar
• Ahn JS , LinJ , OgawaSet.al Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J. Pain Res.10, 1963–1972 (2017).
   PubMed Web of Science ®Google Scholar
• Kapil RP , CiprianoA , FriedmanKet.al Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J. Pain Symptom Manage.46(1), 65–75 (2013).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr , RaffaRB , FleischerC , ZampognaG , TaylorRJr. Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology. J. Pain Res.9, 909–916 (2016).
   PubMed Web of Science ®Google Scholar
• Robinson SE . Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev.8(4), 377–390 (2002).
   PubMedGoogle Scholar
• Steiner DJ , SitarS , WenWet.al Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J. Pain Symptom Manage.42(6), 903–917 (2011).
   PubMed Web of Science ®Google Scholar
• Skvarc NK . Transdermal buprenorphine in clinical practice: results from a multicenter, noninterventional postmarketing study in Slovenia. Pain Manag.2(2), 177–183 (2012).
   PubMedGoogle Scholar
• Priestley T , ChappaAK , MouldDRet.al Converting from transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers. Pain Med.19(10), 1988–1996 (2018).
   PubMed Web of Science ®Google Scholar
• Webster LR , SmithMD , UnalC , FinnA. Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. J. Pain Res.8, 791–798 (2015).
   PubMed Web of Science ®Google Scholar
• goodRX . Belbuca (2020). https://www.goodrx.com/belbuca?dosage=75mcg&form=film&label_override=Belbuca&quantity=60
   Google Scholar
• goodRX . Butrans buprenorphine (2020). https://www.goodrx.com/butrans?dosage=4-patches-of-5mcg&form=carton&label_override=Butrans&quantity=1
   Google Scholar
• Fishman MA , SchererA , TopferJ , KimPSH. Limited access to on-label formulations of buprenorphine for chronic pain as compared with conventional opioids. Pain Med.(2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Aung T , SooS. Drugs induced nausea and vomiting: an overview. J. Pharm. Biol. Sci.11(3), 5–9 (2016).
   Google Scholar
• Webster L , GruenerD , KirbyT , XiangQ , TzanisE , FinnA. Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine. Pain Med.17(5), 899–907 (2016).
   PubMed Web of Science ®Google Scholar
• Raffa RB , HaideryM , HuangHMet.al The clinical analgesic efficacy of buprenorphine. J. Clin. Pharm. Ther.39(6), 577–583 (2014).
   PubMed Web of Science ®Google Scholar
• Opana ER [package insert] . Endo Pharmaceuticals, Inc. PA, USA (2019).
   Google Scholar
• Hale M , KhanA , KutchM , LiS. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr. Med. Res. Opin.26(6), 1505–1518 (2010).
   PubMed Web of Science ®Google Scholar
• Rauck RL , NalamachuS , WildJEet.al Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med.15(6), 975–985 (2014).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr , RaffaRB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J. Pain Res.12, 3299–3317 (2019).
   PubMed Web of Science ®Google Scholar
• Desai SN , BadigerSV , TokurSB , NaikPA. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: a prospective, randomised clinical study. Indian J. Anaesth.61(3), 225–229 (2017).
   PubMed Web of Science ®Google Scholar
• Pattinson KT . Opioids and the control of respiration. Br. J. Anaesth.100(6), 747–758 (2008).
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD (2019). https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf
   Google Scholar
• Webster L , GudinJ , RaffaRBet.al Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med.21(4), 714–723 (2020).
   PubMed Web of Science ®Google Scholar
• Walsh SL , PrestonKL , BigelowGE , StitzerML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther.274(1), 361–372 (1995).
   PubMed Web of Science ®Google Scholar
• Dahan A , YassenA , BijlHet.al Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth.94(6), 825–834 (2005).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services . Report on pain management best practices: updates, gaps, inconsistencies, and recommendations (2019). https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html
   Google Scholar
• Drug Enforcement Administration, Diversion Control Division . Schedules of controlled substances: rescheduling of buprenorphine from Schedule V to Schedule III. (2002). https://www.deadiversion.usdoj.gov/fed_regs/rules/2002/fr1007.htm
   Google Scholar
• United States National Library of Medicine . Single dose crossover study to compare the respiratory drive after administration of belbuca, oxycodone and placebo. (2019). https://clinicaltrials.gov/ct2/show/NCT03996694?term=NCT03996694&rank=1
   Google Scholar
• Preuss CV , KalavaA , KingKC. Prescription of controlled substances: benefits and risks. In: StatPearls. StatPearls Publishing, Treasure Island FL, USA (2019). https://www.ncbi.nlm.nih.gov/books/NBK537318/
   Google Scholar
• United States Department of Health and Human Services . HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. (2019). https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf
   Google Scholar